Selective serotonin reuptake inhibitors enhance cancer immunosurveillance by pleiotropic mechanisms

Authors:
Open Access
Publisher website
Google Scholar
Abstract
In a recent paper published in Cell, Li et al. suggest that selective serotonin reuptake inhibitors (SSRIs) antidepressants act on serotonin transporters on CD8+ T cells to enhance antitumor immunity. Beyond this mechanism, SSRIs can act on malignant cells, as well as on other immune cells, to improve cancer immunosurveillance.
Funding Information
  • Institut Universitaire de France
  • The RHUs Immunolife and LUCA-pi
  • the Ligue contre le Cancer (équipe labellisée);
  • Agence Nationale de la Recherche ((ANR-21-CE44-0016, ANR-23-CE13-0013 (JANUS))
  • the Ligue contre le Cancer
  • Mexican National Council of Science and Technology
  • INCA PLBIO ((PLBIO23-216-2023-181))
  • Fondation pour la Recherche Médicale
  • Hevolution Network on Senescence in Aging
  • Cancéropôle Ile-de-France
  • Association pour la Recherche sur le Cancer
  • Agence national de la recherche ((ANR-22-CE14-0066 VIVORUSH, ANR-23-CE44-0030 COPPERMAC, ANR-23-R4HC-0006 Ener-LIGHT))
  • National support managed by the Agence Nationale de la Recherche under the France 2030 programme
  • European Union Horizon 2020 research and innovation programss Oncobiome
  • The ERA4 Health Cardinoff Grant Ener-LIGHT
  • European Research Council Advanced Investigator Award
  • PAIR-Obésité (INCa_18713)
  • IdEx Université de Paris Cité (ANR-18-IDEX-0001)
  • SIRIC Cancer Research and Personalized Medicine
  • Institut National Du Cancer ((PLBIO23-216-2023-181))
  • Seerave Foundation

This publication has 20 references indexed in Scilit: